文献速递骨软组织肉瘤与黑色素瘤

二甲双胍在EORTC 1325/KEYNOTE-054帕博利珠单抗对比安慰剂治疗已切除高危III期黑色素瘤III期试验中的预后和预测价值

Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
PubMed 文献 · Eur J Cancer · 2023-04-29

本研究基于EORTC 1325/KEYNOTE-054随机对照试验,分析基线二甲双胍使用与已切除高危III期黑色素瘤患者无复发生存(RFS)和无远处转移生存(DMFS)的关联。结果显示二甲双胍使用与RFS(HR 0.87,95%CI 0.52-1.45)和DMFS(HR 0.82,95%CI 0.47-1.44)均无显著关联,与治疗组的交互作用亦不显著。

要点

  • 基线使用二甲双胍者54例(0.5%),与RFS和DMFS均无显著关联。
  • 二甲双胍与治疗组交互作用对RFS(p=0.92)和DMFS(p=0.93)均不显著。
  • BRAF突变患者中二甲双胍与RFS的关联幅度较大但未达显著(HR 0.70,95%CI 0.37-1.33)。

核心结论

  • 二甲双胍使用对已切除高危III期黑色素瘤中帕博利珠单抗的疗效无显著影响。
  • 需要更大规模的研究或汇总分析,特别是探索二甲双胍在BRAF突变黑色素瘤中的可能作用。

研究设计与样本

  • 欧洲癌症研究与治疗组织1325/KEYNOTE-054随机对照试验的二次分析。
  • 已切除高危IIIA、IIIB或IIIC期黑色素瘤患者接受帕博利珠单抗200 mg(n=514)或安慰剂(n=505),每3周一次,共12个月。
  • 采用多变量Cox回归估计二甲双胍与RFS和DMFS的关联,并用交互项模型分析治疗和BRAF突变的效应修饰。

主要发现

  • 基线使用二甲双胍者54例(0.5%)。
  • 二甲双胍与RFS无显著关联(HR 0.87,95%CI 0.52-1.45)。
  • 二甲双胍与DMFS无显著关联(HR 0.82,95%CI 0.47-1.44)。
  • 二甲双胍与治疗组的交互作用对RFS不显著(p=0.92),对DMFS不显著(p=0.93)。
  • BRAF突变患者中二甲双胍与RFS的关联(HR 0.70,95%CI 0.37-1.33)幅度大于BRAF野生型患者(HR 0.98,95%CI 0.56-1.69),但差异未达显著。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更大规模的研究或汇总分析,特别是探索二甲双胍在BRAF突变黑色素瘤中的可能作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin is a commonly prescribed and well-tolerated medication. In laboratory studies, metformin suppresses BRAF wild-type melanoma cells but accelerates the growth of BRAF-mutated cells. This study investigated the prognostic and predictive value of metformin, including with respect to BRAF mutation status, in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 randomised controlled trial. METHODS: Patients with resected high-risk stage IIIA, IIIB, or IIIC melanoma received 200 mg of pembrolizumab (n = 514) or placebo (n = 505) every 3 weeks for twelve months. Pembrolizumab prolonged recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) at approximately 42 months median follow-up (Eggermont et al., TLO, 2021). Multivariable Cox regression was used to estimate associations of metformin with RFS and DMFS. Interaction terms were used to model effect modification by treatment and BRAF mutation. RESULTS: Fifty-four patients (0.5%) used metformin at baseline. Metformin was not significantly associated with RFS (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.52-1.45) and DMFS (HR 0.82, 95% CI 0.47-1.44). The interaction between metformin and the treatment arm was not significant for either RFS (p = 0.92) or DMFS (p = 0.93). Among patients with mutated BRAF, the association of metformin with RFS (HR 0.70, 95% CI 0.37-1.33) was greater in magnitude though not significantly different to those without mutated BRAF (HR 0.98, 95% CI 0.56-1.69). CONCLUSIONS: There was no significant impact of metformin use on pembrolizumab efficacy in resected high-risk stage III melanoma. However, larger studies or pooled analyses are needed, particularly to explore a possible effect of metformin in BRAF-mutated melanoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kennedy OJ, Kicinski M, Valpione S, et al. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. Eur J Cancer. 2023. PMID: 37277264. doi:10.1016/j.ejca.2023.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。